Alivus Life Sciences Ltd Q1 FY27 Results Analysis: EBITDA Margin Expands 650 bps, PAT Jumps 31.7%
Alivus Life Sciences Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 640.41 Cr (+6.40% YoY) and PAT growth of +31.70% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | July 30, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 640.41 Cr (+6.40% YoY) |
| PAT (Q1) | Rs. 160.08 Cr (+31.70% YoY) |
| EBITDA margin | 36.60% (+650 bps YoY) |
| EPS (Q1) | Rs. 13.04 (+31.60% YoY) |
| Market cap | Rs. 13,448.56 Cr |
| CMP | Rs. 1,095.70 |
Quarter Snapshot
Alivus delivered a strong margin beat with EBITDA margin expanding 650 bps YoY to 36.6%, well above the 30-32% guidance band, driven by a 520 bps improvement in material costs. PAT grew 31.7% YoY, though revenue growth of 6.4% was at the lower end of the high single-digit guidance, and QoQ revenue declined 7.1% due to GPL volatility. The debt-free balance sheet and structural margin improvement provide a solid foundation, but revenue acceleration in H2 is needed to meet full-year guidance.
Key Investment Insights
Key Positives
- EBITDA margin expanded 650 bps YoY to 36.6%, the highest in five quarters
- Operating EBITDA margin (ex-other income) expanded 450 bps YoY to 33.1%, confirming structural improvement
- PAT grew 31.7% YoY to Rs.160.08 Cr, with EPS rising 31.6% to Rs.13.04
- Material cost ratio improved 520 bps YoY to 39.5% of revenue, driving margin expansion
- Debt-free balance sheet with Rs.782.40 Cr cash as of March 31, 2026
Risk Factors
- Revenue declined 7.1% QoQ from Q4FY26 peak, consistent with GPL business volatility
- Revenue growth of 6.4% is at the lower end of the high single-digit guidance range, requiring acceleration in H2 to meet full-year guidance
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.